{"id":10826,"date":"2023-12-08T23:51:00","date_gmt":"2023-12-08T15:51:00","guid":{"rendered":"https:\/\/flcube.com\/?p=10826"},"modified":"2024-11-01T23:54:12","modified_gmt":"2024-11-01T15:54:12","slug":"sanofi-eyes-blockbuster-potential-with-12-pipeline-assets-projects-eur-10-billion-in-annual-sales-by-2030","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=10826","title":{"rendered":"Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030"},"content":{"rendered":"\n

Sanofi (NASDAQ: SNY<\/a>) this week outlined its growth potential for the 2024 to 2025 period, highlighting a pipeline of 12 assets poised to achieve blockbuster status, including three projected to exceed EUR 5 billion in sales. The French pharmaceutical giant anticipates generating over EUR 10 billion in annual pharmaceutical revenues by 2030, bolstered by recently launched therapies such as the hemophilia treatment Altuviiio (Fc-VWF-XTEN fusion protein), the cytolytic antibody Sarclisa (isatuximab), and Tzield (teplizumab) for type 1 diabetes management. Additional contributions are expected from upcoming treatments for immune-mediated diseases, including amlitelimab, frexalimab, itepekimab, and tolebrutinib. Furthermore, Sanofi projects an additional EUR 10 billion in annual revenue from its vaccine division by 2030.<\/p>\n\n\n\n

The company also announced plans for a 50% increase in late-stage trials over the next two years, with 25 mid- to late-stage readouts and up to 19 product filings anticipated.<\/p>\n\n\n\n

In a similar vein, The public data reveals that Johnson & Johnson (J&J, NYSE: JNJ<\/a>) has also announced over 15 potential blockbusters, with more than 10 assets expected to surpass USD 5 billion in sales by 2030.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period,…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[39,20,150,149,867,858,147,12],"class_list":["post-10826","post","type-post","status-publish","format-standard","hentry","category-company","tag-diabetes","tag-finance","tag-jj","tag-johnson-johnson","tag-nasdaq-sny","tag-nyse-jnj","tag-sanofi","tag-vaccine"],"yoast_head":"\nSanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period, highlighting a pipeline of 12 assets poised to achieve blockbuster status, including three projected to exceed EUR 5 billion in sales. The French pharmaceutical giant anticipates generating over EUR 10 billion in annual pharmaceutical revenues by 2030, bolstered by recently launched therapies such as the hemophilia treatment Altuviiio (Fc-VWF-XTEN fusion protein), the cytolytic antibody Sarclisa (isatuximab), and Tzield (teplizumab) for type 1 diabetes management.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=10826\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=10826\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-08T15:51:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-01T15:54:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10826#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10826\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030\",\"datePublished\":\"2023-12-08T15:51:00+00:00\",\"dateModified\":\"2024-11-01T15:54:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10826\"},\"wordCount\":182,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Diabetes\",\"Finance\",\"J&J\",\"Johnson & Johnson\",\"NASDAQ: SNY\",\"NYSE: JNJ\",\"Sanofi\",\"Vaccine\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10826#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10826\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=10826\",\"name\":\"Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-12-08T15:51:00+00:00\",\"dateModified\":\"2024-11-01T15:54:12+00:00\",\"description\":\"Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period, highlighting a pipeline of 12 assets poised to achieve blockbuster status, including three projected to exceed EUR 5 billion in sales. The French pharmaceutical giant anticipates generating over EUR 10 billion in annual pharmaceutical revenues by 2030, bolstered by recently launched therapies such as the hemophilia treatment Altuviiio (Fc-VWF-XTEN fusion protein), the cytolytic antibody Sarclisa (isatuximab), and Tzield (teplizumab) for type 1 diabetes management.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10826#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10826\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10826#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030 - Insight, China's Pharmaceutical Industry","description":"Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period, highlighting a pipeline of 12 assets poised to achieve blockbuster status, including three projected to exceed EUR 5 billion in sales. The French pharmaceutical giant anticipates generating over EUR 10 billion in annual pharmaceutical revenues by 2030, bolstered by recently launched therapies such as the hemophilia treatment Altuviiio (Fc-VWF-XTEN fusion protein), the cytolytic antibody Sarclisa (isatuximab), and Tzield (teplizumab) for type 1 diabetes management.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=10826","og_locale":"en_US","og_type":"article","og_title":"Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=10826","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-12-08T15:51:00+00:00","article_modified_time":"2024-11-01T15:54:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=10826#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=10826"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030","datePublished":"2023-12-08T15:51:00+00:00","dateModified":"2024-11-01T15:54:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=10826"},"wordCount":182,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Diabetes","Finance","J&J","Johnson & Johnson","NASDAQ: SNY","NYSE: JNJ","Sanofi","Vaccine"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=10826#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=10826","url":"https:\/\/flcube.com\/?p=10826","name":"Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-12-08T15:51:00+00:00","dateModified":"2024-11-01T15:54:12+00:00","description":"Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period, highlighting a pipeline of 12 assets poised to achieve blockbuster status, including three projected to exceed EUR 5 billion in sales. The French pharmaceutical giant anticipates generating over EUR 10 billion in annual pharmaceutical revenues by 2030, bolstered by recently launched therapies such as the hemophilia treatment Altuviiio (Fc-VWF-XTEN fusion protein), the cytolytic antibody Sarclisa (isatuximab), and Tzield (teplizumab) for type 1 diabetes management.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=10826#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=10826"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=10826#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10826"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10826\/revisions"}],"predecessor-version":[{"id":10827,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10826\/revisions\/10827"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}